文献速递肾移植

多中心移植丙型肝炎感染肾脏研究(MYTHIC)试验的一年结局

One-Year Outcomes of the Multi-Center StudY to Transplant Hepatitis C-InfeCted kidneys (MYTHIC) Trial.
PubMed 文献 · Kidney Int Rep · 2021-12-01

MYTHIC 是一项在7个中心开展的多中心试验,评估HCV D-RNA阳性/R阴性肾移植后2至5天启动8周格卡瑞韦/哌仑他韦(G/P)治疗。63例入组患者中,1年肾移植累积发生率约3.5倍于2055例未选择接受HCV病毒血症供肾的UNOS匹配对照(68% vs 19%,P<0.0001)。30例HCV D-RNA阳性/R阴性肾移植受者均实现HCV治愈,1年生存率93%,移植物功能优良。

要点

  • HCV D-RNA阳性/R阴性肾移植后2至5天启动8周G/P,30例受者均实现HCV治愈。
  • 1年肾移植累积发生率MYTHIC队列68% vs UNOS匹配对照19%(P<0.0001)。
  • 1年生存率93%,中位肌酐1.17 mg/dl(IQR 1.02-1.38)。

核心结论

  • 该多中心试验的1年结果提示,选择接受HCV病毒血症供肾可提高肾移植概率,且1年结局优良。

研究设计与样本

  • MYTHIC为多中心(7个中心)试验,HCV D-RNA阳性/R阴性肾移植后2至5天启动8周格卡瑞韦/哌仑他韦(G/P)治疗。
  • 预设结局包括肾移植概率(与匹配等待名单对照比较)及1年安全性结局、移植物功能和生存。
  • 63例入组患者,其中30例为HCV D-RNA阳性/R阴性肾移植受者;对照为2055例未选择接受HCV病毒血症供肾的UNOS匹配者。
  • 试验注册号NCT03781726。

主要发现

  • 63例入组患者中,1年肾移植累积发生率MYTHIC队列约3.5倍于2055例UNOS匹配对照(68% vs 19%,P<0.0001)。
  • 30例HCV D-RNA阳性/R阴性肾移植受者均实现HCV治愈。
  • 无受者发生临床显著肝病或HCV相关肾损伤。
  • 1年生存率93%,1年移植物功能优良(中位肌酐1.17 mg/dl,IQR 1.02-1.38 mg/dl)。
  • 10例CMV阴性患者接受HCV病毒血症/CMV阳性供肾移植后,发生4例CMV病。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Transplanting kidneys from hepatitis C virus (HCV) viremic donors into HCV-negative patients (HCV D-RNA-positive/R-negative) has evolved from experimental to "standard-of-care" at many centers. Nevertheless, most data derive from single centers and provide only short-term follow-up. METHODS: The Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC) study was a multicenter (7 sites) trial of HCV D-RNA-positive/R-negative kidney transplantation (KT) followed by 8 weeks of glecaprevir/pibrentasvir (G/P) initiated 2 to 5 days post-KT. Prespecified outcomes included probability of KT (vs. matched waitlist comparators) and 1-year safety outcomes, allograft function, and survival. RESULTS: Among 63 enrolled patients, 1-year cumulative incidence of KT was approximately 3.5-fold greater for the MYTHIC cohort versus 2055 matched United Network for Organ Sharing (UNOS) comparators who did not opt-in to receive a kidney from an HCV-viremic donor (68% vs. 19%, P < 0.0001). Of 30 HCV D-RNA-positive/R-negative KT recipients, all achieved HCV cure. None developed clinically significant liver disease or HCV-related kidney injury. Furthermore, 1-year survival was 93% and 1-year graft function was excellent (median creatinine 1.17; interquartile range [IQR]: 1.02-1.38 mg/dl). There were 4 cases of cytomegalovirus (CMV) disease among 10 CMV-negative patients transplanted with a kidney from an HCV-viremic/CMV-positive donor. CONCLUSION: The 1-year findings from this multicenter trial suggest that opting-in for HCV-viremic KT offers can increase probability of KT with excellent 1-year outcomes. Trial Registration: NCT03781726.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Sise ME, Goldberg DS, Schaubel DE, et al. One-Year Outcomes of the Multi-Center StudY to Transplant Hepatitis C-InfeCted kidneys (MYTHIC) Trial. Kidney Int Rep. 2021. PMID: 35155863. doi:10.1016/j.ekir.2021.11.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。